<DOC>
	<DOCNO>NCT00006001</DOCNO>
	<brief_summary>Phase II trial study effectiveness SU5416 treat patient metastatic locally recurrent colorectal cancer . SU5416 may stop growth colorectal cancer stop blood flow tumor .</brief_summary>
	<brief_title>SU5416 Treating Patients With Metastatic Locally Recurrent Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine objective response rate disease stabilization rate patient previously treat metastatic locally recurrent colorectal cancer treat SU5416 . II . Determine median overall survival time progression patient population receive treatment . III . Determine toxicity SU5416 patient . OUTLINE : This multicenter study . Patient receive SU5416 IV 60 minute twice weekly 4 week . Treatment continue minimum 2 course absence unacceptable toxicity disease progression . Patients follow every 2 week 4 week . PROJECTED ACCRUAL : A total 17-37 patient accrue study within 12-18 month .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Semaxinib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic locally recurrent adenocarcinoma colon rectum Progressive disease define new progressive radiologic lesion Measurable disease least 1 dimension least 20 mm conventional technique least 10 mm spiral CT scan Lesions see colonoscopic examination barium study , bone metastasis , CNS lesion , CEA level ascites consider measurable Lesion accessible biopsy within prior radiation port Known history CNS metastasis allow patient treatment , neurologically stable , require oral intravenous steroid anticonvulsant , provide brain scan ( CT MRI ) show absence active residual disease If neurologic sign symptom suggestive CNS metastasis , negative brain scan require PATIENT CHARACTERISTICS : Age : 18 Performance status : WHO 02 Life expectancy : At least 12 week WBC least 3,000/mm3 Platelet count least 75,000/mm3 Bilirubin great 1.5 mg/dL Transaminases great 2.5 time upper limit normal Creatinine great 1.5 mg/dL OR creatinine clearance least 60 mL/min No uncompensated coronary artery disease No history myocardial infarction severe/unstable angina within past 6 month No severe peripheral vascular disease associate diabetes mellitus No deep venous arterial thrombosis within past 3 month No pulmonary embolism within past 3 month Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No significant uncontrolled underlying medical psychiatric illness No serious active infection No concurrent second malignancy except nonmelanoma skin cancer carcinoma situ cervix unless complete therapy consider less 30 % risk relapse No history severe allergic anaphylactic reaction paclitaxel docetaxel PRIOR CONCURRENT THERAPY : No 2 prior chemotherapy regimens metastatic disease At least 4 week since prior chemotherapy No concurrent chemotherapy No concurrent investigational antineoplastic drug No prior radiotherapy site measurable disease At least 4 week since prior radiotherapy recover No concurrent radiotherapy At least 30 day since prior investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
</DOC>